Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 June 2014Website:
http://benitec.comNext earnings report:
13 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:00:09 GMTDividend
Analysts recommendations
Institutional Ownership
BNTC Latest News
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society-
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing.
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study-
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
What type of business is Benitec Biopharma?
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
What sector is Benitec Biopharma in?
Benitec Biopharma is in the Healthcare sector
What industry is Benitec Biopharma in?
Benitec Biopharma is in the Biotechnology industry
What country is Benitec Biopharma from?
Benitec Biopharma is headquartered in United States
When did Benitec Biopharma go public?
Benitec Biopharma initial public offering (IPO) was on 24 June 2014
What is Benitec Biopharma website?
https://benitec.com
Is Benitec Biopharma in the S&P 500?
No, Benitec Biopharma is not included in the S&P 500 index
Is Benitec Biopharma in the NASDAQ 100?
No, Benitec Biopharma is not included in the NASDAQ 100 index
Is Benitec Biopharma in the Dow Jones?
No, Benitec Biopharma is not included in the Dow Jones index
When was Benitec Biopharma the previous earnings report?
No data
When does Benitec Biopharma earnings report?
The next expected earnings date for Benitec Biopharma is 13 February 2025